BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 17854831)

  • 21. Platelet serotonin concentration and monoamine oxidase type B activity in female patients in early, middle and late phase of Alzheimer's disease.
    Muck-Seler D; Presecki P; Mimica N; Mustapic M; Pivac N; Babic A; Nedic G; Folnegovic-Smalc V
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Oct; 33(7):1226-31. PubMed ID: 19602426
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CSF biomarkers predict rate of cognitive decline in Alzheimer disease.
    Kester MI; van der Vlies AE; Blankenstein MA; Pijnenburg YA; van Elk EJ; Scheltens P; van der Flier WM
    Neurology; 2009 Oct; 73(17):1353-8. PubMed ID: 19858456
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma gelsolin is decreased and correlates with rate of decline in Alzheimer's disease.
    Güntert A; Campbell J; Saleem M; O'Brien DP; Thompson AJ; Byers HL; Ward MA; Lovestone S
    J Alzheimers Dis; 2010; 21(2):585-96. PubMed ID: 20571216
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The influence of diagnosis, intra- and inter-person variability on serum and plasma Abeta levels.
    Abdullah L; Paris D; Luis C; Quadros A; Parrish J; Valdes L; Keegan AP; Mathura V; Crawford F; Mullan M
    Neurosci Lett; 2007 Nov; 428(2-3):53-8. PubMed ID: 17964720
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cerebrospinal fluid neuron-specific enolase: a further marker of Alzheimer's disease?
    Palumbo B; Siepi D; Sabalich I; Tranfaglia C; Parnetti L
    Funct Neurol; 2008; 23(2):93-6. PubMed ID: 18671910
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum amyloid p component as a biomarker in mild cognitive impairment and Alzheimer's disease.
    Verwey NA; Schuitemaker A; van der Flier WM; Mulder SD; Mulder C; Hack CE; Scheltens P; Blankenstein MA; Veerhuis R
    Dement Geriatr Cogn Disord; 2008; 26(6):522-7. PubMed ID: 19052452
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Insulin effects on CSF norepinephrine and cognition in Alzheimer's disease.
    Watson GS; Bernhardt T; Reger MA; Cholerton BA; Baker LD; Peskind ER; Asthana S; Plymate SR; Frölich L; Craft S
    Neurobiol Aging; 2006 Jan; 27(1):38-41. PubMed ID: 16298239
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cerebrospinal fluid, serum and plasma protein oxidation in Alzheimer's disease.
    Korolainen MA; Pirttilä T
    Acta Neurol Scand; 2009 Jan; 119(1):32-8. PubMed ID: 18547271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic utility of APOE, soluble CD40, CD40L, and Abeta1-40 levels in plasma in Alzheimer's disease.
    Ait-ghezala G; Abdullah L; Volmar CH; Paris D; Luis CA; Quadros A; Mouzon B; Mullan MA; Keegan AP; Parrish J; Crawford FC; Mathura VS; Mullan MJ
    Cytokine; 2008 Nov; 44(2):283-7. PubMed ID: 18835787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma aminothiol compounds, but not serum tumor necrosis factor receptor II and soluble receptor for advanced glycation end products, are related to the cognitive impairment in Alzheimer's disease and mild cognitive impairment patients.
    Hernanz A; De la Fuente M; Navarro M; Frank A
    Neuroimmunomodulation; 2007; 14(3-4):163-7. PubMed ID: 18073509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced soluble CD40 ligand and Alzheimer's disease: evidence of a possible pathogenetic role.
    Desideri G; Cipollone F; Necozione S; Marini C; Lechiara MC; Taglieri G; Zuliani G; Fellin R; Mezzetti A; di Orio F; Ferri C
    Neurobiol Aging; 2008 Mar; 29(3):348-56. PubMed ID: 17123665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progression of mild cognitive impairment to Alzheimer's disease: improved diagnostic value of the combined use of N200 latency and beta-amyloid(1-42) levels.
    Papaliagkas VT; Anogianakis G; Tsolaki MN; Koliakos G; Kimiskidis VK
    Dement Geriatr Cogn Disord; 2009; 28(1):30-5. PubMed ID: 19628938
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decreased EEG synchronization and its correlation with symptom severity in Alzheimer's disease.
    Park YM; Che HJ; Im CH; Jung HT; Bae SM; Lee SH
    Neurosci Res; 2008 Oct; 62(2):112-7. PubMed ID: 18672010
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low serum VEGF levels are associated with Alzheimer's disease.
    Mateo I; Llorca J; Infante J; Rodríguez-Rodríguez E; Fernández-Viadero C; Peña N; Berciano J; Combarros O
    Acta Neurol Scand; 2007 Jul; 116(1):56-8. PubMed ID: 17587256
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased midkine levels in sera from patients with Alzheimer's disease.
    Salama RH; Muramatsu H; Shimizu E; Hashimoto K; Ohgake S; Watanabe H; Komatsu N; Okamura N; Koike K; Shinoda N; Okada S; Iyo M; Muramatsu T
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 May; 29(4):611-6. PubMed ID: 15866365
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive value of rapid decline in mini mental state examination in clinical practice for prognosis in Alzheimer's disease.
    Soto ME; Andrieu S; Cantet C; Reynish E; Ousset PJ; Arbus C; Gillette-Guyonnet S; Nourhashémi F; Vellas B;
    Dement Geriatr Cogn Disord; 2008; 26(2):109-16. PubMed ID: 18617740
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BDNF is a novel marker of cognitive function in ageing women: the DR's EXTRA Study.
    Komulainen P; Pedersen M; Hänninen T; Bruunsgaard H; Lakka TA; Kivipelto M; Hassinen M; Rauramaa TH; Pedersen BK; Rauramaa R
    Neurobiol Learn Mem; 2008 Nov; 90(4):596-603. PubMed ID: 18707012
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides.
    Höglund K; Hansson O; Buchhave P; Zetterberg H; Lewczuk P; Londos E; Blennow K; Minthon L; Wiltfang J
    Neurodegener Dis; 2008; 5(5):268-76. PubMed ID: 18309230
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Hydrogen proton MR spectroscopy of posterior portion cingulate gyrus of patients with Alzheimer's disease: a case control study].
    Wang T; Xiao SF; Li X; Wang Y; Ding B; Ling HW; Chen KM
    Zhonghua Yi Xue Za Zhi; 2009 Jan; 89(1):37-40. PubMed ID: 19489242
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma carbonic anhydrase II protein is elevated in Alzheimer's disease.
    Jang BG; Yun SM; Ahn K; Song JH; Jo SA; Kim YY; Kim DK; Park MH; Han C; Koh YH
    J Alzheimers Dis; 2010; 21(3):939-45. PubMed ID: 20634585
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.